PlainPharmaWatch

CMS Open Payments · Program Year 2024

Ferring SA de CV

Ferring SA de CV reported $18,026.97 across General Payments, Research, and Ownership to 10 physicians and teaching hospitals across 10 transactions.

$18.0K Below-median payer
All-tracks total
10 Below-median volume
Transactions
10 Below-median reach
Recipients
#1548
of 1,925 companies

Ferring SA de CV reported $18,026.97 across all CMS Open Payments tracks (General + Research + Ownership) to 10 physicians and teaching hospitals in Program Year 2024 - ranking #1548 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $18,026.97, averaging $1.8K per recipient.

Ferring SA de CV's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

17/100

Total payments

F

10/100

Transaction volume

F

10/100

Physician reach

F

10/100

Payment type diversity

F

37/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer ferring-sa-de-cv Ferring SA de CV

$18.0K · #1548/1,925 · 0.0% industry · PY2024

  • TOT $18.0K
  • RANK #1548
  • SHARE 0.0%
  • TXN 10
  • RCP 10
  • CAT 3
  • GEN $18.0K
  • TOP1 51.3%
  • PY 2024

Nearest volume peer: Solco Biomedical Corporation ($18.0K)

Ostial Corporation$18.2KFerring SA de CV (this)$18.0KSolco Biomedical Corporation$18.0KCentrix Inc$17.9KAvantec Vascular Corporation$17.9K
All-tracks payment totals near Ferring SA de CV (CMS Open Payments PY2024)

Ferring SA de CV sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Ferring SA de CV

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Ferring SA de CV that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

2 transactions worth $13.3K make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 73.9% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Ferring SA de CV's 3-category general-payment breakdown at $13.3K, 73.9% of the reported total.

How Ferring SA de CV divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$13.3K2. Travel and Lodging$3.8K3. Food and Beverage$893.90
Payment Type Amount Transactions
Consulting Fee $13.3K 2
Travel and Lodging $3.8K 6
Food and Beverage $893.90 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $18,026.97 (100.0%) of $18,026.97 in this company's General Payments records across 2 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Ferring SA de CV

The five named recipients with the highest reported General Payments from this company

Richard Legro$9.2KJulio Loret de Mola$8.8K
  1. 1

    Richard Legro

    $9,239.32 across 5 reported transactions

  2. 2

    Julio Loret de Mola

    $8,787.65 across 5 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Ferring SA de CV ranks #1548 of 1,925 by total payments (bottom 20% by spend) but is notably more concentrated than that alone would suggest -- #359 of 1,838 by HHI (top 20% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.

00.30.50.81.14997.95009.450215032.65044.1Total payments ($M)Concentration (HHI, 0-10,000)
Ferring SA de CV (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Ferring SA de CV's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ferring SA de CV.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Ferring SA de CV.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Ferring SA de CV ranks #1548 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Ferring SA de CV's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.